Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Alliance Global Partners increased their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP opened at $0.13 on Thursday. Tonix Pharmaceuticals has a one year low of $0.13 and a one year high of $26.56. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The firm’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $3.28. The stock has a market capitalization of $392,957.60, a P/E ratio of 0.00 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. As a group, analysts expect that Tonix Pharmaceuticals will post -18 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the Securities & Exchange Commission. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.